(Total Views: 769)
Posted On: 05/15/2020 2:44:48 PM
Post# of 155038
It'll be interesting to see if IncellDX can see and quantify the diagnostic benefits between the SC and IV initial dose in the eIND patients (hopefully compassionate use soon).
Even if they modify the trial protocol for initial IV dose, IMO that will not be a big deal and will only to help patients not the trial outcome......unlike remdesivir that attempted to prove an ounce of efficacy with their revised trial endpoint/s.
Even if they modify the trial protocol for initial IV dose, IMO that will not be a big deal and will only to help patients not the trial outcome......unlike remdesivir that attempted to prove an ounce of efficacy with their revised trial endpoint/s.
(2)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
